Telomir Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.27	0	0	-
Cash & Short-Term Investments	1.27	0	0	-
Cash Growth	102753.86%	-13.25%	-	-
Prepaid Expenses	0.06	0	-	-
Other Current Assets	-	0.43	0.05	-
Total Current Assets	1.32	0.44	0.05	-
Long-Term Deferred Charges	-	4.34	-	-
Total Assets	1.32	4.77	0.05	-
Accounts Payable	0.59	0.71	0.4	0.02
Short-Term Debt	0.09	0.63	0.58	0.12
Total Current Liabilities	0.68	1.34	0.99	0.14
Total Liabilities	0.68	1.34	0.99	0.14
Additional Paid-In Capital	31.24	17.5	0.06	0.06
Retained Earnings	-30.6	-14.06	-0.99	-0.14
Comprehensive Income & Other	-	-	-	-0.06
Shareholders' Equity	0.64	3.44	-0.94	-0.14
Total Liabilities & Equity	1.32	4.77	0.05	-
Total Debt	0.09	0.63	0.58	0.12
Net Cash (Debt)	1.17	-0.63	-0.58	-0.12
Net Cash Per Share	0.04	-0.02	-0.02	-
Filing Date Shares Outstanding	29.76	29.61	27.1	-
Total Common Shares Outstanding	29.76	28.61	26.83	-
Working Capital	0.64	-0.9	-0.94	-0.14
Book Value Per Share	0.02	0.12	-0.03	-
Tangible Book Value	0.64	3.44	-0.94	-0.14
Tangible Book Value Per Share	0.02	0.12	-0.03	-

Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q